- Home
- KMDA vs BBNX Comparison
KMDA vs BBNX Comparison
Compare KMDA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- BBNX
- Stock Information
- Founded
- KMDA 1990
- BBNX 2015
- Country
- KMDA Israel
- BBNX United States
- Employees
- KMDA N/A
- BBNX N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- KMDA Health Care
- BBNX Health Care
- Exchange
- KMDA Nasdaq
- BBNX Nasdaq
- Market Cap
- KMDA 380.7M
- BBNX 435.7M
- IPO Year
- KMDA N/A
- BBNX 2025
- Fundamental
- Price
- KMDA $6.89
- BBNX $13.20
- Analyst Decision
- KMDA Strong Buy
- BBNX Strong Buy
- Analyst Count
- KMDA 3
- BBNX 6
- Target Price
- KMDA $14.67
- BBNX $26.67
- AVG Volume (30 Days)
- KMDA 53.8K
- BBNX 393.3K
- Earning Date
- KMDA 05-14-2025
- BBNX 05-06-2025
- Dividend Yield
- KMDA 2.89%
- BBNX N/A
- EPS Growth
- KMDA 66.67
- BBNX N/A
- EPS
- KMDA 0.25
- BBNX N/A
- Revenue
- KMDA $160,953,000.00
- BBNX $69,830,000.00
- Revenue This Year
- KMDA $14.01
- BBNX $29.49
- Revenue Next Year
- KMDA $9.24
- BBNX $34.93
- P/E Ratio
- KMDA $27.37
- BBNX N/A
- Revenue Growth
- KMDA 12.93
- BBNX 38911.17
- 52 Week Low
- KMDA $4.74
- BBNX $8.89
- 52 Week High
- KMDA $9.15
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- KMDA 58.32
- BBNX N/A
- Support Level
- KMDA $6.69
- BBNX N/A
- Resistance Level
- KMDA $7.10
- BBNX N/A
- Average True Range (ATR)
- KMDA 0.16
- BBNX 0.00
- MACD
- KMDA 0.05
- BBNX 0.00
- Stochastic Oscillator
- KMDA 72.00
- BBNX 0.00
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.